We also demonstrated that, in vivo when the ligand-liposome encapsulated wt p53 was injected I.V., preexisting SCCHN and prostate cancer xenografts completely regressed after radiotherapy.

Discover the potential of chronotherapy, a groundbreaking approach to cancer treatment that aligns chemotherapy with your ...

When researchers at the University of Michigan Rogel Cancer Center first identified a new subtype of aggressive prostate ...

Originally published on talker.news, part of the BLOX Digital Content Exchange .

When researchers at the University of Michigan Rogel Cancer Center first identified a new subtype of aggressive prostate ...

Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), today announced it will present comprehensive preclinical ...

Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove ...

Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...

University of Michigan researchers have made significant strides in understanding and treating a new, aggressive subtype of ...

Researchers at the University of Michigan Rogel Cancer Center have recently uncovered a novel subtype of aggressive prostate ...